Expert Review of Proteomics, published by TAYLOR & FRANCIS LTD, is a distinguished journal that focuses on the latest advancements in the field of proteomics, a critical area within biochemistry and molecular biology. With an ISSN of 1478-9450 and E-ISSN 1744-8387, this journal has been pivotal in disseminating high-quality research from its inception in 2004 to its planned convergence in 2024. Its influential position is reflected in its 2023 rankings, placing it in the Q2 category for both Biochemistry and Molecular Biology, alongside respectable Scopus rankings that rank it 118th and 141st in its respective categories. Despite its non-open access structure, Expert Review of Proteomics provides researchers and professionals with a vital platform for critical reviews and insights into proteomic methodologies, thus contributing significantly to the global scientific community. By bridging theoretical research with practical applications, it serves as an essential resource for those dedicated to advancing their knowledge and expertise in this dynamic field.

All Life is a distinguished academic journal published by TAYLOR & FRANCIS LTD, based in the United Kingdom, focusing on the interdisciplinary realms of agricultural and biological sciences, biochemistry, genetics, and neuroscience. With the ISSN 2689-5293 and E-ISSN 2689-5307, this open-access journal aims to disseminate high-quality research from 2020 to 2024, facilitating a wider reach and impact across various fields. Notably, it holds a Q3 ranking in both Agricultural and Biological Sciences, as well as Biochemistry, Genetics and Molecular Biology, and a Q4 ranking in Neuroscience, reflecting its growing presence in these disciplines. All Life aims to foster collaboration among researchers, professionals, and students, encouraging innovative approaches in understanding life sciences. By delivering timely insights and thought-provoking discussions, the journal plays a crucial role in advancing knowledge and promoting interdisciplinary dialogue in the evolving landscape of life sciences research.

MOLECULAR BIOLOGY, published by PLEIADES PUBLISHING INC, serves as a vital repository for the dissemination of innovative research within the fields of biochemistry, genetics, and molecular biology. With an ISSN of 0026-8933 and an E-ISSN of 1608-3245, this journal has been a mainstay in the scientific community since its inception, embracing its deep historical roots from 1971 to the present. Recognized for its qualitative contributions, MOLECULAR BIOLOGY is ranked in the Q3 quartile for Biophysics and Q4 for Structural Biology, placing it among select journals in its domain. Researchers and students alike benefit from its rigorous peer-reviewed articles, which focus on all aspects of molecular mechanisms and interactions. The journal's inclusion in prestigious databases underlines its commitment to academic excellence. The editorial board is dedicated to fostering the sharing of influential findings, making it an essential resource for advancing knowledge and innovation in molecular biology.

Clinical Proteomics is a leading open-access journal, published by BMC since 2011, that aims to advance the field of proteomics by providing a platform for the dissemination of original research, critical reviews, and technological advancements in the analysis of proteins and their roles in health and disease. With an ISSN of 1542-6416 and E-ISSN 1559-0275, this esteemed journal covers a broad scope, converging years of research from 2004 to 2024. As a distinguished publication, it holds a Q1 ranking in Clinical Biochemistry and Q2 in both Molecular Biology and Molecular Medicine, reflecting its significance in the scientific community. Clinical Proteomics' commitment to open access ensures that its content is readily available to researchers, professionals, and students worldwide, facilitating the exchange of knowledge and fostering collaborative efforts in proteomic studies. Situated in the United Kingdom, this journal plays a pivotal role in shaping the future of biomedical research, appealing to anyone keen on the integration of proteomics in clinical practice and molecular investigation.

Mass Spectrometry Letters is a pioneering open-access journal published by the Korean Society for Mass Spectrometry, specializing in the diverse fields of analytical chemistry, biochemistry, and spectroscopy. Established in 2010, this journal aims to disseminate groundbreaking research and advancements in mass spectrometry and its applications across various scientific domains. Though currently categorized in the Q4 quartile in key analytical fields, Mass Spectrometry Letters serves as an essential platform for researchers, professionals, and students to share innovative methodologies, emerging trends, and practical applications of mass spectrometry, thus fostering collaboration and advancing knowledge in the scientific community. With a commitment to open access, articles published since 2010 are readily available, enabling widespread distribution and engagement within the international research community. Located in Daejeon, South Korea, and actively converging research through 2024, the journal holds the potential to grow its impact and relevance within the dynamic landscape of mass spectrometry.

MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

MASS SPECTROMETRY REVIEWS, published by Wiley, is a premier academic journal dedicated to advancing the field of mass spectrometry and its applications across a multitude of scientific disciplines. With an ISSN of 0277-7037 and an E-ISSN of 1098-2787, the journal has established itself as a vital resource within the realms of Analytical Chemistry, Biochemistry, Genetics, Condensed Matter Physics, and Spectroscopy, achieving Q1 status across these categories in 2023. As a testament to its significant contribution to scholarly research, it boasts impressive Scopus rankings, including a rank of #2 out of 76 in Chemistry - Spectroscopy and #4 out of 156 in Chemistry - Analytical Chemistry, placing it in the 97th percentile and above. Emphasizing high-quality, peer-reviewed research, MASS SPECTROMETRY REVIEWS serves as an essential platform for researchers, professionals, and students aiming to stay abreast of cutting-edge developments and methodologies in mass spectrometry. The journal is committed to fostering a deeper understanding of mass spectrometric techniques while also contributing to interdisciplinary advancements, making it a valuable addition to any academic library. Authors seeking to disseminate their work in a journal with a strong reputation and impact in the scientific community will find MASS SPECTROMETRY REVIEWS an ideal venue.

Genome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.

Proteomes, published by MDPI since 2013, is a notable open access journal that occupies a critical place in the realms of Biochemistry, Clinical Biochemistry, Molecular Biology, and Structural Biology. Based in Switzerland, this journal not only promotes the dissemination of high-quality research pertaining to protein structures and functions but also emphasizes interdisciplinary approaches that bridge various fields of biomedical science. With a Category Quartile ranking of Q2 across multiple pertinent categories in 2023, Proteomes boasts a competitive impact within the scientific community, evidenced by its robust Scopus rankings. Researchers, professionals, and students are invited to explore a wealth of pioneering studies and reviews that are made freely accessible, aligning with global trends in open scientific communication. Whether contributing original research or seeking to expand their knowledge, the journal serves as an invaluable resource for anyone engaged in the evolving landscape of proteomics.

PROTEIN AND PEPTIDE LETTERS is a prominent peer-reviewed journal published by Bentham Science Publishers Ltd, specializing in the dynamic fields of biochemistry and structural biology. With an ISSN of 0929-8665 and a corresponding E-ISSN of 1875-5305, the journal has been a pivotal platform for researchers since its inception in 1994. Spanning various aspects of protein and peptide research, it aims to disseminate groundbreaking findings that enhance our understanding of molecular mechanisms and therapeutic applications. Although categorized in the Q3 quartile for biochemistry and medicine, and Q4 in structural biology within the 2023 metrics, it remains a valuable resource in the academic arena, offering insight into the latest research and advancements. As the journal converges towards its 2024 milestone, it continues to reflect the evolving landscape of molecular research. While it currently does not offer open access, the accessibility to its impactful content is essential for students, professionals, and researchers invested in these critical scientific disciplines.